{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:59:27Z","timestamp":1761929967776},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B lymphoid cells that exhibits diffuse growth patterns. Patients may present with nodal and\/or extranodal disease. The most common extranodal site is the gastrointestinal tract, while skin is less common.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a case of secondary skin involvement of an original gastric DLBCL, which has achieved a complete response after treatment with chidamide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Initially, the diagnosis of gastric DLBCL is clear, and this patient responded well to systemic chemotherapy (rituximab + cyclophosphamide + epirubicin + vincristine + prednisone) after 8 cycles. Thirty months later, some rapidly enlarging skin nodules on his arm were found. These skin nodules were diagnosed as secondary cutaneous DLBCL based on the clinical features, positron emission tomography-computed tomography, and histomorphologic and immunohistochemical expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Steroids, interferon-\u03b1, and radiation had little therapeutic effect. We treated the patient with chidamide at 30\u200amg twice per week in combination with dexamethasone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The skin nodules regressed 3 weeks later. During the 1-year follow-up period, the patient is still in treatment with chidamide without adverse reactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the first case of secondary skin DLBCL reported to exhibit a complete response to chidamide, which provides a novel therapeutic strategy for secondary skin DLBCL. However, more cases are still needed to further validate its efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013093","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:09:10Z","timestamp":1544292550000},"page":"e13093","source":"Crossref","is-referenced-by-count":6,"title":["Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide"],"prefix":"10.1097","volume":"97","author":[{"given":"Dan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Imaging, Institute of Hematology of PLA, Changhai Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240524","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"R2-20240524","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"R3-20240524","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"R4-20240524","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23638","article-title":"Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology, and end results database","volume":"89","author":"Castillo","year":"2014","journal-title":"Am J Hematol"},{"key":"R5-20240524","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2340\/00015555-2139","article-title":"Secondary cutaneous diffuse large B-cell lymphoma has a higher international prognostic index score and worse prognosis than diffuse large B-cell lymphoma, leg type","volume":"96","author":"Lee","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R6-20240524","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"key":"R7-20240524","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1067\/mjd.2000.110071","article-title":"Relative frequency of various forms of primary cutaneous lymphomas","volume":"43","author":"Zackheim","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R8-20240524","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V99.3.800","article-title":"Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients","volume":"99","author":"Fink-Puches","year":"2002","journal-title":"Blood"},{"key":"R9-20240524","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R10-20240524","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"R11-20240524","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R12-20240524","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"R13-20240524","first-page":"589","article-title":"Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment","volume":"147","author":"Paulli","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"R14-20240524","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"R15-20240524","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"R16-20240524","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2133.2003.05649.x","article-title":"Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"key":"R17-20240524","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2015.1040012","article-title":"Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy","volume":"57","author":"Akhtari","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R18-20240524","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R19-20240524","doi-asserted-by":"crossref","first-page":"e70522","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS ONE"},{"key":"R20-20240524","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R21-20240524","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"R22-20240524","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2016.1164140","article-title":"An overview of investigational histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma","volume":"25","author":"Apuri","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"R23-20240524","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"key":"R24-20240524","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R25-20240524","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors","volume":"147","author":"Gloghini","year":"2009","journal-title":"Br J Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:03:32Z","timestamp":1716584612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00007"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":25,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013093","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}